Condition
Kidney Transplant Immunosuppression
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 4 (3)
Trial Status
Completed1
Terminated1
Enrolling By Invitation1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01424345Phase 4TerminatedPrimary
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
NCT04786067Phase 4CompletedPrimary
Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
NCT06336863Not ApplicableEnrolling By InvitationPrimary
Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
NCT06114953Phase 4UnknownPrimary
Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients
Showing all 4 trials